pyridostigmine bromide has been researched along with 2019 Novel Coronavirus Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariatti, A; Galassi, G; Iori, E; Marchioni, A; Rispoli, V | 1 |
| Afshari, FT; Debenham, P; Parida, A; Solanki, GA | 1 |
| Govindarajan, R; Singh, S | 1 |
| Koc, G; Odabasi, Z; Tan, E | 1 |
| Arias-Martínez, S; Audelo-Cruz, BM; Belaunzarán-Zamudio, PF; Calva, JJ; Carbajal-Morelos, SL; Caro-Vega, Y; Crabtree-Ramírez, B; Crispín, JC; Fragoso-Saavedra, S; García-González, HB; González-Duarte, A; Iruegas-Nunez, DA; Luqueño-Martínez, V; Nuñez, I; Quintero-Villegas, A; Sierra-Madero, J; Valdés-Ferrer, SI | 1 |
| B, SK; Muralidhar Reddy, Y; Murthy, JMK; Osman, S | 1 |
1 review(s) available for pyridostigmine bromide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Myasthenia gravis complicating the surgical management of achondroplasia: a case-based update.
Topics: Achondroplasia; Anesthetics; Azathioprine; Child; Constriction, Pathologic; COVID-19; Female; Humans; Myasthenia Gravis; Nucleotides; Pandemics; Pyridostigmine Bromide; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Cholinergic; Spinal Cord Compression | 2022 |
1 trial(s) available for pyridostigmine bromide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 inf
Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Humans; Inflammation; Lung; Pandemics; Pneumonia, Viral; Pyridostigmine Bromide; Respiration, Artificial; SARS-CoV-2 | 2020 |
4 other study(ies) available for pyridostigmine bromide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Aged; ChAdOx1 nCoV-19; Cholinesterase Inhibitors; COVID-19; COVID-19 Vaccines; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Fever; Humans; Male; Myalgia; Myasthenia Gravis; Pyridostigmine Bromide; SARS-CoV-2; Treatment Outcome | 2022 |
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Disease Progression; Female; Glucocorticoids; Humans; Hypercapnia; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Myasthenia Gravis; Mycophenolic Acid; Pandemics; Plasma Exchange; Pneumonia, Viral; Prednisone; Pyridostigmine Bromide; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness Index; Thymectomy; Tomography, X-Ray Computed | 2020 |
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
Topics: Antimalarials; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Male; Middle Aged; Myasthenia Gravis; Pandemics; Pneumonia, Viral; Pyridostigmine Bromide; SARS-CoV-2 | 2020 |
Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?
Topics: Aged; COVID-19; Humans; Male; Middle Aged; Myasthenia Gravis; Pyridostigmine Bromide; Receptors, Cholinergic; SARS-CoV-2 | 2021 |